Lapatinib Teva

Lapatinib, the active ingredient in Lapatinib Teva, is a tyrosine kinase inhibitor presented as a 1250 mg tablet for oral use. It treats HER2‑positive metastatic breast cancer and advanced gastric cancer in adult patients.

GNH USA supplies Lapatinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Lapatinib targets HER2/neu and EGFR pathways and is indicated for specific HER2‑positive cancers. - HER2‑positive metastatic breast cancer: used in combination with chemotherapy to improve progression‑free survival. - HER2‑positive advanced gastric cancer: combined with capecitabine and trastuzumab to target HER2‑positive disease. - HER2‑positive postmenopausal breast cancer with hormone‑receptor positivity: used with letrozole for disease control.

Lapatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea - Rash or skin irritation - Nausea - Fatigue - Hand‑foot syndrome

Serious or Rare Side Effects: - Hepatotoxicity (elevated transaminases, hepatitis) - QT interval prolongation leading to arrhythmia - Severe skin reactions such as Stevens‑Johnson syndrome - Interstitial lung disease or pneumonitis

When prescribing lapatinib, clinicians should observe several precautionary measures to minimize risk. - Cardiac monitoring: assess left ventricular ejection fraction before and during therapy. - Liver function: check ALT/AST levels regularly. - QT interval: obtain baseline ECG and monitor for prolongation. - Concomitant CYP3A4 inhibitors: avoid strong inhibitors or adjust dose. - Severe hepatic impairment: use with caution or avoid. - Store at below 25°C: keep in the original pack, protect from moisture.

Lapatinib interacts with several medicines through metabolic pathways and cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lapatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of arrhythmia.

Moderate Interactions (Monitor Closely): - Antacids or H2‑blockers: may affect absorption; separate dosing by at least 2 hours. - Warfarin: monitor INR as lapatinib may alter anticoagulant effect. - Digoxin: observe serum levels for potential changes.